Goodpasture syndrome surgery

Jump to navigation Jump to search

Goodpasture syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Goodpasture syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Echocardiography

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Goodpasture syndrome surgery On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Goodpasture syndrome surgery

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Goodpasture syndrome surgery

CDC on Goodpasture syndrome surgery

Goodpasture syndrome surgery in the news

Blogs on Goodpasture syndrome surgery

Directions to Hospitals Treating Goodpasture syndrome

Risk calculators and risk factors for Goodpasture syndrome surgery

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Ali Poyan Mehr, M.D. [2]; Associate Editor(s)-in-Chief: Krzysztof Wierzbicki M.D. [3] Akshun Kalia M.B.B.S.[4]

Overview

Surgery is not the first-line treatment option for patients with Goodpasture syndrome. Renal transplantation is usually reserved for patients who present with undetectable circulating anti-glomerular basement antibodies in serum for 12 months and atleast 6 months after stopping the use of cytotoxic agents.

Surgery

References

  1. Menn-Josephy H, Beck LH (2015). "Recurrent glomerular disease in the kidney allograft". Front Biosci (Elite Ed). 7: 135–48. PMID 25553369.
  2. "Notice". Kidney Int Suppl (2011). 2 (2): 139. 2012. doi:10.1038/kisup.2012.9. PMC 4089568. PMID 25028634.
  3. Chen M, Kallenberg CG (2010). "ANCA-associated vasculitides--advances in pathogenesis and treatment". Nat Rev Rheumatol. 6 (11): 653–64. doi:10.1038/nrrheum.2010.158. PMID 20924413.

Template:WH Template:WS